drugset / Trial / NCT01356914

Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden

NCT01356914

Phase 2 Completed 20 enrolled Bristol-Myers Squibb
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of the study is to determine whether treatment with BMS-914392 is safe, well tolerated and associated with a reduction of atrial fibrillation burden in patients with paroxysmal atrial fibrillation and permanent pacemaker.

Timeline

Start
2011-05
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-914392 Unknown 10 mg Oral
Subject BMS-914392 Unknown 20 mg Oral

Indications